97 related articles for article (PubMed ID: 17994638)
1. Activity-dependent neurotrophic factor, ADNF, determines the structure characteristics of Colivelin, a fusion protein of ADNF9 and Humanin analog.
Arakawa T; Niikura T; Arisaka F; Kita Y
J Pept Sci; 2008 May; 14(5):631-6. PubMed ID: 17994638
[TBL] [Abstract][Full Text] [Related]
2. Short neuroprotective peptides, ADNF9 and NAP, are structurally disordered and monomeric in PBS.
Arakawa T; Niikura T; Arisaka F; Kita Y
Int J Biol Macromol; 2009 Jul; 45(1):8-11. PubMed ID: 19447252
[TBL] [Abstract][Full Text] [Related]
3. Development of a femtomolar-acting humanin derivative named colivelin by attaching activity-dependent neurotrophic factor to its N terminus: characterization of colivelin-mediated neuroprotection against Alzheimer's disease-relevant insults in vitro and in vivo.
Chiba T; Yamada M; Hashimoto Y; Sato M; Sasabe J; Kita Y; Terashita K; Aiso S; Nishimoto I; Matsuoka M
J Neurosci; 2005 Nov; 25(44):10252-61. PubMed ID: 16267233
[TBL] [Abstract][Full Text] [Related]
4. The structure analysis of Humanin analog, AGA-(C8R)HNG17, by circular dichroism and sedimentation equilibrium: comparison with the parent molecule.
Arisaka F; Niikura T; Arakawa T; Kita Y
Int J Biol Macromol; 2008 Aug; 43(2):88-93. PubMed ID: 18456318
[TBL] [Abstract][Full Text] [Related]
5. Structure analysis of activity-dependent neurotrophic factor 9 by circular dichroism and sedimentation equilibrium.
Arakawa T; Niikura T; Tajima H; Arisaka F; Kita Y
J Mol Neurosci; 2007; 33(3):262-7. PubMed ID: 17952635
[TBL] [Abstract][Full Text] [Related]
6. The secondary structure analysis of a potent Ser14Gly analog of antiAlzheimer peptide, Humanin, by circular dichroism.
Arakawa T; Niikura T; Tajima H; Kita Y
J Pept Sci; 2006 Oct; 12(10):639-42. PubMed ID: 16835886
[TBL] [Abstract][Full Text] [Related]
7. Structure changes of natively disordered Humanin in the presence of lipid.
Hirano A; Shiraki K; Niikura T; Arakawa T; Kita Y
Int J Biol Macromol; 2010 Apr; 46(3):375-9. PubMed ID: 20116397
[TBL] [Abstract][Full Text] [Related]
8. Neuroprotection against neurodegenerative diseases: development of a novel hybrid neuroprotective peptide Colivelin.
Chiba T; Nishimoto I; Aiso S; Matsuoka M
Mol Neurobiol; 2007 Feb; 35(1):55-84. PubMed ID: 17519506
[TBL] [Abstract][Full Text] [Related]
9. Solution structure of Ser14Gly-humanin, a potent rescue factor against neuronal cell death in Alzheimer's disease.
Benaki D; Zikos C; Evangelou A; Livaniou E; Vlassi M; Mikros E; Pelecanou M
Biochem Biophys Res Commun; 2006 Oct; 349(2):634-42. PubMed ID: 16945331
[TBL] [Abstract][Full Text] [Related]
10. Activity-dependent neurotrophic factor: structure-activity relationships of femtomolar-acting peptides.
Brenneman DE; Hauser J; Neale E; Rubinraut S; Fridkin M; Davidson A; Gozes I
J Pharmacol Exp Ther; 1998 May; 285(2):619-27. PubMed ID: 9580606
[TBL] [Abstract][Full Text] [Related]
11. The biological activity of Humanin analogs correlates with structure stabilities in solution.
Arakawa T; Niikura T; Kita Y
Int J Biol Macromol; 2011 Jul; 49(1):93-7. PubMed ID: 21510972
[TBL] [Abstract][Full Text] [Related]
12. Humanin structural versatility and interaction with model cerebral cortex membranes.
Pistolesi S; Rossini L; Ferro E; Basosi R; Trabalzini L; Pogni R
Biochemistry; 2009 Jun; 48(22):5026-33. PubMed ID: 19378954
[TBL] [Abstract][Full Text] [Related]
13. Structure of three Humanin peptides with different activities upon interaction with liposome.
Hirano A; Shiraki K; Niikura T; Arakawa T; Kita Y
Int J Biol Macromol; 2011 Mar; 48(2):360-3. PubMed ID: 21215775
[TBL] [Abstract][Full Text] [Related]
14. Nuclear factor-kappaB mediates the cell survival-promoting action of activity-dependent neurotrophic factor peptide-9.
Glazner GW; Camandola S; Mattson MP
J Neurochem; 2000 Jul; 75(1):101-8. PubMed ID: 10854252
[TBL] [Abstract][Full Text] [Related]
15. Structural and dynamical studies of Humanin in water and TFE/water mixture: a molecular dynamics simulation.
Mehrnejad F; Chaparzadeh N
J Biomol Struct Dyn; 2008 Oct; 26(2):255-62. PubMed ID: 18597547
[TBL] [Abstract][Full Text] [Related]
16. D-Ser-containing humanin shows promotion of fibril formation.
Hayashi K; Sasabe J; Chiba T; Aiso S; Utsunomiya-Tate N
Amino Acids; 2012 Jun; 42(6):2293-7. PubMed ID: 21735222
[TBL] [Abstract][Full Text] [Related]
17. Humanin and colivelin: neuronal-death-suppressing peptides for Alzheimer's disease and amyotrophic lateral sclerosis.
Matsuoka M; Hashimoto Y; Aiso S; Nishimoto I
CNS Drug Rev; 2006; 12(2):113-22. PubMed ID: 16958985
[TBL] [Abstract][Full Text] [Related]
18. Solution structure of humanin, a peptide against Alzheimer's disease-related neurotoxicity.
Benaki D; Zikos C; Evangelou A; Livaniou E; Vlassi M; Mikros E; Pelecanou M
Biochem Biophys Res Commun; 2005 Apr; 329(1):152-60. PubMed ID: 15721287
[TBL] [Abstract][Full Text] [Related]
19. Zinc(II) binds to the neuroprotective peptide humanin.
Armas A; Sonois V; Mothes E; Mazarguil H; Faller P
J Inorg Biochem; 2006 Oct; 100(10):1672-8. PubMed ID: 16844225
[TBL] [Abstract][Full Text] [Related]
20. The multiple T-maze in vivo testing of the neuroprotective effect of humanin analogues.
Kunesová G; Hlavácek J; Patocka J; Evangelou A; Zikos C; Benaki D; Paravatou-Petsotas M; Pelecanou M; Livaniou E; Slaninova J
Peptides; 2008 Nov; 29(11):1982-7. PubMed ID: 18647630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
